Mineralys Therapeutics Inc (NASDAQ:MLYS) has a beta value of -0.16 and has seen 0.81 million shares traded in the recent trading session. The company, currently valued at $716.89M, closed the recent trade at $14.39 per share which meant it lost -$0.57 on the day or -3.84% during that session. The MLYS stock price is -27.1% off its 52-week high price of $18.29 and 42.74% above the 52-week low of $8.24.
The consensus among analysts is that Mineralys Therapeutics Inc (MLYS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.03.
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
Sporting -3.84% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MLYS stock price touched $14.39 or saw a rise of 21.32%. Year-to-date, Mineralys Therapeutics Inc shares have moved 16.86%, while the 5-day performance has seen it change 45.01%. Over the past 30 days, the shares of Mineralys Therapeutics Inc (NASDAQ:MLYS) have changed 46.64%.
Wall Street analysts have a consensus price target for the stock at $30, which means that the shares’ value could jump 52.03% from the levels at last check today. The projected low price target is $30.0 while the price target rests at a high of $30.0. In that case, then, we find that the latest price level in today’s session is -108.48% off the targeted high while a plunge would see the stock gain -108.48% from the levels at last check today.
Mineralys Therapeutics Inc (MLYS) estimates and forecasts
The company’s shares have gained 28.10% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -170.42% over the past 5 years. Earnings growth for 2025 is a modest -3.44% while over the next 5 years, the company’s earnings are expected to decrease by -3.06%.
MLYS Dividends
Mineralys Therapeutics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s Major holders
The top two institutional holders are CATALYS PACIFIC, LLC with over 9.19 million shares worth more than $107.58 million. As of 2024-06-30, CATALYS PACIFIC, LLC held 18.629% of shares outstanding.
The other major institutional holder is SAMSARA BIOCAPITAL, LLC, with the holding of over 5.07 million shares as of 2024-06-30. The firm’s total holdings are worth over $59.38 million and represent 10.2822% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 1.57% shares in the company for having 781.46 shares of worth $11.12 million while later fund manager owns 784.65 shares of worth $11.17 million as of Dec 31, 2024, which makes it owner of about 1.57% of company’s outstanding stock.
